Suppression of mTOR via Akt-dependent and -independent mechanisms in selenium-treated colon cancer cells: involvement of AMPKα1

被引:43
作者
Lee, Yun-Kyoung [1 ]
Park, Song Yi [2 ]
Kim, Young-Min [2 ]
Kim, Dong Chool [3 ]
Lee, Won Sup [4 ]
Surh, Young-Joon [5 ]
Park, Ock Jin [1 ]
机构
[1] Hannam Univ, Dept Food & Nutr, Taejon 305811, South Korea
[2] Hannam Univ, Dept Biol Sci, Taejon 305811, South Korea
[3] Gyeongsang Natl Univ, Sch Med, Dept Pathol, Inst Hlth Sci, Jinju 660702, South Korea
[4] Gyeongsang Natl Univ, Sch Med, Dept Internal Med, Jinju 660702, South Korea
[5] Seoul Natl Univ, Coll Pharm, Natl Res Lab Mol Carcinogenesis & Chemoprevent, Seoul 151742, South Korea
关键词
ACTIVATED PROTEIN-KINASE; MAMMALIAN TARGET; RAPAMYCIN; AMPK; PATHWAY; GROWTH; PREVENTION; SUPPLEMENTATION; IDENTIFICATION; INHIBITION;
D O I
10.1093/carcin/bgq040
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Activation of the mammalian target of rapamycin (mTOR) pathway promotes tumorigenesis, and inhibiting the mammalian target of rapamycin complex 1 (mTORC1) has emerged as an attractive target for suppressing tumor growth. We found that selenium treatment of HT-29 colon cancer cells suppressed mTORC1 through Akt-independent and -dependent pathways. In Akt-independent mTORC1 inhibition in selenium-treated colon cancer cells, adenosine monophosphate-activated protein kinase (AMPK) alpha(1) was crucial for suppression of mTORC1 activity. In contrast, the Akt-dependent mTORC1 inhibition by selenium did not require AMPK alpha(1). The importance of the AMPK alpha(1)-mTORC1 pathway in mediating the antiproliferative action of selenium was examined in xenograft tumors, and the suppression of mTORC1 as well as Akt was concomitant with an increase in AMPK alpha(1) activity. These findings suggest that the antiproliferative effect of selenium is mediated by an Akt-independent AMPK alpha(1)/mTORC1 pathway or by the Akt/tuberous sclerosis complex 2 /mTORC1 pathway.
引用
收藏
页码:1092 / 1099
页数:8
相关论文
共 42 条
[1]   PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2 [J].
Balendran, A ;
Casamayor, A ;
Deak, M ;
Paterson, A ;
Gaffney, P ;
Currie, R ;
Downes, CP ;
Alessi, DR .
CURRENT BIOLOGY, 1999, 9 (08) :393-404
[2]   Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer [J].
Carretero, J. ;
Medina, P. P. ;
Blanco, R. ;
Smit, L. ;
Tang, M. ;
Roncador, G. ;
Maestre, L. ;
Conde, E. ;
Lopez-Rios, F. ;
Clevers, H. C. ;
Sanchez-Cespedes, M. .
ONCOGENE, 2007, 26 (11) :1616-1625
[3]   REGULATION OF PROTEIN SERINE-THREONINE PHOSPHATASE TYPE-2A BY TYROSINE PHOSPHORYLATION [J].
CHEN, J ;
MARTIN, BL ;
BRAUTIGAN, DL .
SCIENCE, 1992, 257 (5074) :1261-1264
[4]   Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin a randomized controlled trial - A randomized controlled trial [J].
Clark, LC ;
Combs, GF ;
Turnbull, BW ;
Slate, EH ;
Chalker, DK ;
Chow, J ;
Davis, LS ;
Glover, RA ;
Graham, GF ;
Gross, EG ;
Krongrad, A ;
Lesher, JL ;
Park, HK ;
Sanders, BB ;
Smith, CL ;
Taylor, JR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (24) :1957-1963
[5]   An Amino Acid Shuffle Activates mTORC1 [J].
Cohen, Adiel ;
Hall, Michael N. .
CELL, 2009, 136 (03) :399-401
[6]   Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome [J].
Corradetti, MN ;
Inoki, K ;
Bardeesy, N ;
DePinho, RA ;
Guan, KL .
GENES & DEVELOPMENT, 2004, 18 (13) :1533-1538
[7]   Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis [J].
Cully, M ;
You, H ;
Levine, AJ ;
Mak, TW .
NATURE REVIEWS CANCER, 2006, 6 (03) :184-192
[8]   Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells [J].
Dowling, Ryan J. O. ;
Zakikhani, Mahvash ;
Fantus, I. George ;
Pollak, Michael ;
Sonenberg, Nahum .
CANCER RESEARCH, 2007, 67 (22) :10804-10812
[9]  
Duffield-Lillico AJ, 2002, CANCER EPIDEM BIOMAR, V11, P630
[10]   Targeting PI3K signalling in cancer: opportunities, challenges and limitations [J].
Engelman, Jeffrey A. .
NATURE REVIEWS CANCER, 2009, 9 (08) :550-562